The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125478851 12547885 1 I 20160705 20160712 20160712 EXP US-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023582 GLENMARK GOLOMB B A, KOSLIK H J, REDD A J.. FLUOROQUINOLONE-INDUCED SERIOUS, PERSISTENT, MULTISYMPTOM ADVERSE EFFECTS.. BMJ CASE REPORTS. 2015 0.00 Y 0.00000 20160712 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125478851 12547885 1 PS LEVOFLOXACIN. LEVOFLOXACIN 1 Unknown 750 MG, QD N 200250 750 MG
125478851 12547885 2 C LANSOPRAZOLE. LANSOPRAZOLE 1 Unknown 30 MG, OD 0 30 MG QD
125478851 12547885 3 C CETIRIZINE CETIRIZINE HYDROCHLORIDE 1 Unknown 10 MG, OD 0 10 MG QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125478851 12547885 1 Epididymitis
125478851 12547885 2 Product used for unknown indication
125478851 12547885 3 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
125478851 12547885 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125478851 12547885 Affective disorder
125478851 12547885 Atrophy
125478851 12547885 Bradycardia
125478851 12547885 Cognitive disorder
125478851 12547885 Eye disorder
125478851 12547885 Fatigue
125478851 12547885 Fibromyalgia
125478851 12547885 Gastrointestinal disorder
125478851 12547885 Gastrointestinal motility disorder
125478851 12547885 Muscular weakness
125478851 12547885 Polyneuropathy
125478851 12547885 Respiratory muscle weakness
125478851 12547885 Tachycardia
125478851 12547885 Tendon disorder
125478851 12547885 Toxicity to various agents
125478851 12547885 Visual impairment

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found